MRNA - Biotech Bonanza: 2022 Biotech Outlook In A Hawkish Fed Year
- Biotechs struggled in 2021 as indexes lagged the broader market.
- So far in 2022, biotechs have dropped sharply as interest rate uncertainty has created a risk-off market. A rising interest rate environment remains the biggest risk for biotechs.
- With the S&P 500 biotech index halved from its peak a year ago, the index is closer to approaching a bottom though near-term risks remain.
- M&A can rise due to a combination of factors.
- Biotech indexes will have an uphill year and the industry will remain a stock picker's market.
For further details see:
Biotech Bonanza: 2022 Biotech Outlook In A Hawkish Fed Year